<DOC>
	<DOCNO>NCT02718430</DOCNO>
	<brief_summary>Phase I study patient metastatic colorectal cancer liver metastasis second third line therapy examine safety , efficacy , immune biomarkers treatment VXM01</brief_summary>
	<brief_title>VXM01 Phase I Study Patients With Metastatic Colorectal Cancer With Liver Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Informed consent , include liver metastasis biopsy , sign date 2 . Histologically cytologically confirm colorectal cancer , exclude primary tumor appendiceal origin ( participant eligible enroll irrespective Kirsten rat sarcoma viral oncogene homolog ( KRAS ) mutation status ) 3 . Male female patient must postmenopausal least 2 year surgically sterile . 4 . Confirmed metastatic colorectal cancer ( Stage IV ) 5 . Presence nonresectable liver metastasis Accessibility liver metastasis appropriate biopsy sample Adequate coagulation parameter include platelet count ≥100,000/mm3 Absence concomitant medication could represent contraindication biopsy ( e.g. , antiplatelet drug include aspirin , ticlopidine , clopidogrel , IIb/IIIa receptor antagonist , nonsteroidal antiinflammatory drug [ NSAIDs ] , vitamin K antagonist anticoagulant ) 6 . The participant receive firstline irinotecan oxaliplatinbased therapy without combination target antibody metastatic disease ) Experienced radiographic disease progression firstline therapy , b ) Experienced radiographic disease progression ≤ 6 month last dose firstline therapy , c ) Discontinued part firstline therapy due toxicity experience radiographic disease progression ≤ 6 month last dose firstline therapy 7 . Receipt 3 prior systemic therapy regimen metastatic disease 8 . Measurable nonmeasurable disease base Response Evaluation Criteria Solid Tumors , Version 1.1 ( RECIST v. 1.1 ) 9 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 10 . Life expectancy &gt; 3 month 11 . Adequate renal , hepatic , bone marrow function 12 . Leukocytes ≥4.0 x 109 / L 13 . Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 14 . Platelet count ≥ 100,000/mm3 15 . Hemoglobin ≥ 9 g/dL ( posttransfusion ) 16. International normalize ratio ( INR ) ≤ 1.5 17 . Activated partial thromboplastin time ( aPTT ) ≤ 1.5 time upper limit normal ( ULN ) 18 . Bilirubin ≤ 1.5 time ULN 19 . ALT AST ≤ 2.5 time ULN 20 . Creatinine ≤ 2.0 mg/dL 21 . Proteinuria ≤ 1+ urine dipstick OR ≤ 1 g 24hour urine collection 22 . Patients able understand nature purpose study include possible risk , willing comply requirement , provide write informed consent participate study 1 . Concomitant treatment antiangiogenic therapy progression disease 2 . Treatment clinical trial within 30 day screen . 3 . Gastric bypass 4 . Ileostoma 5 . Other anatomical change gastrointestinal tract , interfere gastrointestinal passage , except colostoma colon bypass 6 . Untreated CNS metastasis . Participants treat brain metastasis eligible clinically stable regard neurologic function , steroid cranial irradiation end least 2 week prior randomization , surgical resection perform least 28 day prior randomization . No evidence Grade great equal 1 CNS hemorrhage base pretreatment Magnetic Resonance Imaging ( MRI ) intravenous ( IV ) contrast CT scan 7 . Significant traumatic injury surgery within past 4 week 8 . Cerebrovascular accident , transient ischemic attack , subarachnoid hemorrhage within past 6 month 9 . Other malignancy within past 5 year except adequately treat carcinoma situ cervix , and/or basal cell skin cancer , and/or early endometrial carcinoma 10 . Preexisting sensory motor neuropathy ≥ grade 2 11 . History evidence CNS disease ( e.g. , uncontrolled seizure ) neurological examination unless adequately treat standard medical therapy 12 . History evidence thrombotic hemorrhagic disorder , include intracranial hemorrhage 13 . Uncontrolled hypertension ( i.e. , blood pressure &gt; 160/100 mm Hg ) 14 . Clinically significant cardiovascular disease , include follow : Myocardial infarction unstable angina within past 6 month New York Heart Association class IIIIV congestive heart failure Poorly control cardiac arrhythmia despite medication , except rate control atrial fibrillation 15 . Peripheral vascular disease ≥ grade 3 ( i.e. , symptomatic interfering activity daily live require repair revision ) 16 . Positive antityphoid IgG/IgM antibody accord onsite test Day 0 17 . Hemoptysis within 6 month randomization 18 . Esophageal varix 19 . Upper low gastrointestinal bleeding within 6 month randomization 20 . Nonhealing wound , incomplete wound healing , bone fracture history gastrointestinal ulcer within three year inclusion , positive gastroscopy within 3 month inclusion 21 . Gastrointestinal fistula 22 . Thrombolysis therapy within 4 week randomization 23 . Presence acute chronic systemic infection 24 . Major surgical procedure , open biopsy within 4 week randomization 25 . Chronic concurrent therapy within 2 week initial treatment period ( Day 1 Day 7 ) : Corticosteroids ( except steroid adrenal failure emesis prophylaxis 4 mg daily dose ) immunosuppressive agent Antibiotics Bevacizumab antiangiogenic treatment 26 . Known multidrug resistant gramnegative bacteria 27 . History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation study result render patient high risk treatment complication 28 . Women childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>